Illicit drug use

In 2018, 6.9% of the total disease burden among Indigenous Australians was due to illicit drug use. Illicit drug use includes burden from opioids, amphetamines, cocaine and cannabis and other illicit drug use, as well as unsafe injecting practices. Illicit drug use was the 4th leading risk factor contributing to total disease burden.

These estimates reflect the amount of disease burden that could have been avoided if all Indigenous Australians had not used illicit drugs.

Illicit drug use contributed to burden for 15 diseases and injuries; 4 types of injuries, 3 infections, liver cancer, chronic liver disease and 4 types of mental and substance use disorders (see ABDS 2018 Risk factor estimates for Indigenous Australians data table S1). The linked diseases differed by type of illicit drug.

Individual drug use types

Of the individual drug use types, opioid use was the leading illicit drug use risk, contributing to 2.2% of the total burden among Indigenous Australians in 2018. This was followed by amphetamine use (1.9% of total burden in 2018) and cannabis use (1.6%).

This interactive data visualisation shows the burden attributable to illicit drug use among Indigenous Australians by type of illicit drug. The main section shows a horizontal bar graph which can be customised to report data according to year, sex and measure of attributable burden. Each bar represents the attributable burden due to a particular type of illicit drug.

How much burden was attributable to illicit drug use?

In 2018 among Indigenous Australians, illicit drug use was responsible for almost all burden due to drug use disorders (excluding alcohol) (99%), 86% of poisoning, 34% of suicide and self-inflicted injuries, and 27% of chronic liver disease and liver cancer.

This interactive data visualisation shows the burden attributable to illicit drug use among Indigenous Australians by linked disease. The main section shows a horizontal bar graph which can be customised to report data according to year, sex, type of illicit drug and measure of attributable burden. Each bar represents the attributable burden of the disease linked to illicit drug use.

How did burden attributable to illicit drug use vary by age and sex?

The burden due to illicit drug use was estimated in Indigenous Australians aged 15 and over. Disease burden due to illicit drug use was highest among Indigenous Australians aged between 25–34, after which, burden gradually decreased with increasing age.

Indigenous males experienced more than twice the total burden from illicit drug use than Indigenous females. Drug use disorders (excluding alcohol) were the largest contributor to the illicit drug use attributable burden in Indigenous Australians aged between 15 and 64. Poisoning and suicide & self-inflicted injuries were also large contributors to the attributable burden in both Indigenous males and Indigenous females of the same age groups.

This interactive data visualisation shows the amount of burden attributable to illicit drug use among Indigenous Australians by age group and linked disease. The main section shows a stacked bar graph which can be customised to report data according to year, sex, disease group, type of illicit drug and measure of attributable burden. Each bar represents the attributable burden within a particular age group. Each bar is also split into separate components with each colour representing a disease linked to illicit drug use.

How has disease burden due to illicit drug use changed over time?

The age-standardised rate of total burden attributable to illicit drug use among Indigenous Australians increased by 76.5% between 2003 and 2018 (from 12.9 to 22.8 DALY per 1,000 population).

This interactive data visualisation shows the rate of burden attributable to illicit drug use among Indigenous Australians by year. The main section shows a horizontal bar graph which can be customised to report data according to year, sex and measure of attributable burden. Each bar represents the attributable burden within a particular year due to illicit drug use.